Resverlogix value decimated by RVX-208 failure
This article was originally published in Scrip
Resverlogix lost nearly all of its value on 27 June when its stock sank 92.6% from $2.99 to $0.22 per share – dropping its market cap from $221.9 million to $16.4 million in one and a half hours of trading – after the Canadian company disclosed the failure of its lead cardiovascular drug candidate and only clinical asset RVX-208 in the Phase IIb ASSURE study.
You may also be interested in...
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.